INVO Fertility, Inc. reported its financial results for the third quarter of 2025, revealing a total revenue of approximately $1.76 million, a 23% increase from $1.43 million in the same period last year. For the nine months ending September 30, 2025, the company generated $5.26 million in revenue, up from $4.85 million in the prior year. The growth in revenue was primarily attributed to organic growth in its Wisconsin and Atlanta clinics, which have become significant contributors to the company's overall performance.
Despite the revenue increase, INVO Fertility experienced a net loss of $2.64 million for the quarter, compared to a loss of $1.63 million in Q3 2024. The nine-month net loss for 2025 reached approximately $25.33 million, significantly higher than the $5.47 million loss reported for the same period in 2024. The increase in losses was largely driven by non-cash expenses, including a $1.4 million impairment loss related to a noncompetition agreement and a $1.6 million loss from debt extinguishment.
Operationally, INVO Fertility has made strategic moves to enhance its market position. The company divested 80.1% of its stake in NAYA Therapeutics in June 2025, refocusing its efforts on the fertility market. As of September 30, 2025, INVO operated two INVO Centers and one IVF clinic in the U.S., with plans to expand its clinic network further. The company also reported a significant increase in its employee headcount, reflecting its growth strategy.
The company’s balance sheet showed total assets of approximately $18.83 million as of September 30, 2025, down from $46.45 million at the end of 2024. This decline was primarily due to the divestiture of NAYA and the associated impairment losses. INVO Fertility's cash position decreased to $355,891 from $619,520 at the end of 2024, while total liabilities were reported at $12.98 million, down from $26.24 million. The company’s stockholders' equity also fell to $5.85 million from $12.75 million.
Looking ahead, INVO Fertility aims to continue its growth trajectory by acquiring additional profitable IVF clinics and expanding its existing operations. The company has indicated that it will need to secure further funding to support its liquidity needs and operational strategies, as it anticipates ongoing losses until it can achieve positive cash flow from operations. The management remains optimistic about the long-term potential of the fertility market, driven by increasing demand for assisted reproductive technologies.
About INVO Fertility, Inc.
INVO Fertility, Inc. is a healthcare services company specializing in assisted reproductive technology (ART). It operates fertility clinics, including INVO Centers utilizing its proprietary INVOcell device for in vivo fertilization, and acquires existing IVF clinics. The company focuses on expanding access to affordable fertility treatments, leveraging innovative devices and clinic networks to serve a large, underserved global market.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.